CSTL
CASTLE BIOSCIENCES INC
+1.12 (+3.16%)36.60USD111K成交股數1.1B市值–本益比(近四季)3.1股價營收比+20.1%營收年增(近四季)2026-11-02下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 104M+18% | 83.7M-3% | 83.0M-3% | 86.2M-1% | 88.0M+21% | 86.3M+40% | 85.8M+71% | 87.0M+107% | 73.0M | 61.5M | 50.1M | 42.0M |
| 營業成本 | 23.7M | 20.5M | 18.7M | 17.6M | 16.4M | 16.2M | 15.6M | 14.5M | 13.9M | 11.3M | 11.1M | 10.2M |
| 毛利 | 79.8M+12% | 63.1M-10% | 64.3M-8% | 68.6M-5% | 71.6M+21% | 70.1M+40% | 70.2M+80% | 72.5M+128% | 59.1M | 50.2M | 39.1M | 31.9M |
| 毛利率 | 77.1% | 75.5% | 77.5% | 79.5% | 81.4% | 81.3% | 81.8% | 83.3% | 81.0% | 81.6% | 77.9% | 75.8% |
| 研發費用 | 14.5M | 14.4M | 13.0M | 12.8M | 12.6M | 11.8M | 12.3M | 14.1M | 13.8M | 12.9M | 13.3M | 14.4M |
| 銷售管理費用 | 66.1M | 64.9M | 55.9M | 58.1M | 58.6M | 50.0M | 50.5M | 51.1M | 48.5M | 44.6M | 44.7M | 46.8M |
| 營業利益 | −3.1M-89% | −18.4M-554% | −6.8M-234% | −4.3M-185% | −27.9M+410% | 4.1M-142% | 5.1M-124% | 5.0M-116% | −5.5M | −9.6M | −21.2M | −31.5M |
| 營業利益率 | -3.0% | -22.0% | -8.2% | -4.9% | -31.7% | 4.7% | 5.9% | 5.8% | -7.5% | -15.7% | -42.2% | -75.0% |
| 稅後淨利 | −2.1M-92% | −14.5M-251% | −501K-122% | 4.5M-49% | −25.8M+920% | 9.6M-239% | 2.3M-112% | 8.9M-131% | −2.5M | −6.9M | −18.8M | −29.2M |
| 淨利率 | -2.0% | -17.4% | -0.6% | 5.2% | -29.4% | 11.1% | 2.6% | 10.3% | -3.5% | -11.2% | -37.5% | -69.5% |
| 稀釋 EPS | -0.07-92% | -0.49-253% | -0.02-125% | 0.15-52% | -0.90+900% | 0.32-223% | 0.08-111% | 0.31-128% | -0.09 | -0.26 | -0.70 | -1.10 |
| 稀釋股數 | 30.4M | 29.9M | 29.1M | 29.5M | 28.6M | 29.3M | 29.4M | 28.7M | 27.5M | 26.8M | 26.7M | 26.6M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 62.1M | 63.8M | 85.6M | 82.2M | 89.7M | 120M | 95.0M | 85.6M | 82.9M | 91.2M | 95.9M | 115M |
| 應收帳款 | 48.3M | 42.3M | 49.5M | 52.3M | 56.4M | 51.2M | 50.3M | 46.0M | 42.7M | 37.0M | 31.3M | 27.7M |
| 存貨 | 10.6M | 10.5M | 8.7M | 8.4M | 6.8M | 8.1M | 6.6M | 8.0M | 7.6M | 5.8M | 6.1M | 4.5M |
| 總資產 | 561M | 548M | 563M | 545M | 502M | 531M | 515M | 487M | 459M | 436M | 425M | 427M |
| 有息負債 | 7.2M | 8.4M | 10.0M | 8.1M | 8.9M | 9.7M | 10.0M | 10.0M | 10.0M | – | – | 0.00 |
| 總負債 | 91.1M | 86.4M | 95.7M | 89.4M | 61.4M | 75.4M | 73.5M | 63.4M | 56.0M | 50.2M | 46.6M | 41.7M |
| 股東權益 | 470M | 461M | 467M | 455M | 440M | 456M | 441M | 424M | 402M | 386M | 379M | 385M |
| 負債比 | 16.2% | 15.8% | 17.0% | 16.4% | 12.2% | 14.2% | 14.3% | 13.0% | 12.2% | 11.5% | 11.0% | 9.8% |
| 淨現金(現金 − 有息負債) | 55.0M | 55.4M | 75.5M | 74.1M | 80.8M | 110M | 84.9M | 75.6M | 72.9M | – | – | 115M |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −22.1M | – | – | −6.0M-12% | – | – | – | −6.8M | – | – | −25.4M |
| 資本支出 | – | 12.5M | – | – | 4.7M | – | – | – | 9.2M | – | – | 3.3M |
| 自由現金流 | – | −34.6M | – | – | −10.8M-33% | – | – | – | −16.0M | – | – | −28.8M |
| 折舊攤銷 | – | 3.9M | – | – | 29.8M | – | – | – | 3.3M | – | – | 2.9M |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -41.3% | – | – | -12.2% | – | – | – | -21.9% | – | – | -68.5% |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 344M
| Reportable | 344M | 100.0% | +3.7% |
|---|
產品／服務2025 年度 · 344M
| Dermatologic | 216M | 62.9% | -15.8% |
|---|---|---|---|
| Non Dermatologic | 128M | 37.1% | +70.3% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 344M | +3.7% | −24.2M | -7.0% | -0.83 | 28.3M |
| FY2024 | 332M | +51.1% | 18.2M | 5.5% | 0.62 | 36.5M |
| FY2023 | 220M | +60.4% | −57.5M | -26.1% | -2.14 | −19.2M |
| FY2022 | 137M | +45.7% | −67.1M | -49.0% | -2.58 | −47.3M |
| FY2021 | 94.1M | +50.2% | −31.3M | -33.3% | -1.24 | −22.5M |
| FY2020 | 62.6M | +20.8% | −10.3M | -16.4% | -0.54 | 5.1M |
| FY2019 | 51.9M | +127.6% | 5.3M | 10.2% | -0.21 | 6.1M |
| FY2018 | 22.8M | – | −6.4M | -27.9% | -5.33 | −12.6M |